Healthcare
Live Price
Offline$11.69
-1.27% today
1Y Change
-6.70%
Window
Jun 20, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 20, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Straumann Holding AG (SAUHY) is a Healthcare stock with a market cap of $13.47B and listed on OTC. The stock last traded around $11.69 and down 6.7% across the available one-year price window (Jun 20, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -0.6%, EPS growth of -10.8%, a dividend yield of 1.2%. What stands out right now is revenue -0.6%, EPS -10.8%, free cash flow -0.2% with operating margin 44.1% and ROIC 30.1%. The dividend is present but secondary, with a yield around 1.2%. Valuation already assumes a fairly strong business story at P/E 37.6 and price/sales 5.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SAUHY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SAUHY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SAUHY Max Drawdown
-31.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SAUHY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.0B
-12.9% YoY
FY Net Income
$396.1M
-8.9% YoY
Free Cash Flow
$441.0M
+99.6% YoY
Revenue Growth
-0.6%
EPS Growth
-10.8%
Gross Margin
68.7%
Net Margin
13.7%
Income statement
CHF
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.5B | 2.5B | 2.4B | 2.3B | 2.0B |
| Gross Profit | 1.7B | 1.8B | 1.8B | 1.7B | 1.5B |
| Operating Income | 524M | 601M | 411M | 535M | 543M |
| EBITDA | 524M | 726M | 715M | 671M | 609M |
| Net Income | 342M | 388M | 246M | 435M | 396M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CHF
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 476M | 375M | 410M | 696M | 880M |
| Total Assets | 3.8B | 3.6B | 3.4B | 3.5B | 3.1B |
| Total Liabilities | 1.6B | 1.6B | 1.6B | 1.6B | 1.6B |
| Shareholder Equity | 2.2B | 2.0B | 1.8B | 1.9B | 1.5B |
| Total Debt | 651M | 414M | 412M | 782M | 707M |
| Net Debt | 175M | 38M | 2M | 9M | -169M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
562M
+35.0% YoY
Capital Expenditures
121M
+38.1% YoY
Free Cash Flow
441M
+99.6% YoY
Key ratios
Gross Margin
68.7%
Operating Margin
44.1%
Net Margin
13.7%
ROE
16.9%
Debt / Equity
0.30x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.